Prophylactic β-blocking Treatment after Myocardial Infarction

  • G. Permanyer Miralda
  • E. Galve Basilio
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 81)


In recent years, random, double-blind, placebo controlled clinical trials have demonstrated a significant reduction in mortality (up to about 2 years) in patients given β-blocking agents from the 5th to 18th day after acute myocardial infarction (AMI) [1–7]. In some of these trials, a specific reduction in the rate of sudden death [1, 2] and reinfarction [1, 7] has been shown to exist.


Acute Myocardial Infarction Blocker Treatment Refractory Heart Failure Postinfarctional Patient Norwegian Multicenter Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–807.CrossRefGoogle Scholar
  2. 2.
    Beta-blocker Heart Attack Trial Research Group: A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707–1714.CrossRefGoogle Scholar
  3. 3.
    Improvement in prognosis of myocardial infarction by long-term ß-adrenoreceptor blockade using practolol. A multicenter international study. Br Med J 1975; 3: 735–740.Google Scholar
  4. 4.
    Taylor SH, Silke B, Ebbut A, Sutton GC, Prout BJ, Burley DM: Long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982; 307: 1293–1301.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werko L: Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet, 1974; 2: 1157–1160.PubMedCrossRefGoogle Scholar
  6. 6.
    Australian and Swedish Pindolol Study Group: The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J, 1983; 4: 367–375.Google Scholar
  7. 7.
    Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet, 1982; 1: 1142–1147.PubMedCrossRefGoogle Scholar
  8. 8.
    Hjamarson A, Elmfeldt D, Herlitz J, Holberg S, Malek I, Nyberg G, et al.: Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet, 1981; 2: 823–827.CrossRefGoogle Scholar
  9. 9.
    Frishman HW, Furberg CD, Friedewald WT: ß-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med, 1984; 310: 830–837.PubMedCrossRefGoogle Scholar
  10. 10.
    Singh BN, Phil D, Venkatesh N: Prevention of myocardial reinfarction and of sudden death in survivors of acute myocardial infarction: role of prophylactic ßωadrenoreceptor blockade. Am Heart J, 1984; 107: 189–200.PubMedCrossRefGoogle Scholar
  11. 11.
    Hampton JR: The use of ß-blockers for the reduction of mortality after myocardial infarction. Eur Heart J, 1981; 2: 259–268.PubMedGoogle Scholar
  12. 12.
    Lewis JA: ß-blockade after myocardial infarction. A statistical view. Br J Clin Pharmac, 1982; 14: 15S-21S.Google Scholar
  13. 13.
    Breckenridge A: Should every survivor of a heart attack be given a ßωblocker? Part II. Evidence from a clinical pharmacological standpoint. Br Med J, 1982; 285: 37–39.CrossRefGoogle Scholar
  14. 14.
    Prichard BNC: Mechanisms of myocardial infarct prevention with ß-adrenoreceptor blocking drugs. Drugs, 1983; 25 (Suppl 2): 295–302.CrossRefGoogle Scholar
  15. 15.
    Wilhelmsson C, Vedin A: Principles and practice of treatment with ß-blockers in myocardial infarction. Drugs, 1983; 25 (Suppl 2): 308–313.CrossRefGoogle Scholar
  16. 16.
    Moss AJ: Postinfarction therapy with ß-blockers: who should be treated? Int J Cardiol, 1982; 1: 343–349.PubMedCrossRefGoogle Scholar
  17. 17.
    Griggs TR, Wagner GS, Gettes LS: ß-adrenergic blocking agents after myocardial infarction: an undocumented need in patients at lowest risk. J Am Coll Cardiol, 1983; 1: 1530–1533.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanz G, Castañer A, Betriu A, Magrina J, Roig E et al: Determinants of prognosis in survivors of myocardial infarction. A prospective clinical angiographic study. N Engl J Med, 1982; 306: 1065–1070.PubMedCrossRefGoogle Scholar
  19. 19.
    Olsson G, Rehnqvist N: Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol. Circulation, 1984; 69: 1129–1134.PubMedCrossRefGoogle Scholar
  20. 20.
    Marshall RCM, Wisenberg G, Schelbert HR, Henze E: Effect of oral propanolol on rest, exercise and postexercise left ventricular performance in normal subjects and patients with coronary artery disease. Circulation, 1981; 63: 572–583.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • G. Permanyer Miralda
  • E. Galve Basilio

There are no affiliations available

Personalised recommendations